These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 23717468)

  • 1. Pemetrexed induced thymidylate synthase inhibition in non-small cell lung cancer patients: a pilot study with 3'-deoxy-3'-[¹⁸F]fluorothymidine positron emission tomography.
    Frings V; van der Veldt AA; Boellaard R; Herder GJ; Giovannetti E; Honeywell R; Peters GJ; Thunnissen E; Hoekstra OS; Smit EF
    PLoS One; 2013; 8(5):e63705. PubMed ID: 23717468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early detection of pemetrexed-induced inhibition of thymidylate synthase in non-small cell lung cancer with FLT-PET imaging.
    Chen X; Yang Y; Berger I; Khalid U; Patel A; Cai J; Farwell MD; Langer C; Aggarwal C; Albelda SM; Katz SI
    Oncotarget; 2017 Apr; 8(15):24213-24223. PubMed ID: 27655645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Subset of Non-Small Cell Lung Cancer Patients Treated with Pemetrexed Show
    Aravind P; Popat S; Barwick TD; Soneji N; Lythgoe M; Sreter KB; Lozano-Kuehne JP; Bergqvist M; Patel N; Aboagye EO; Kenny LM
    Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of thymidylate synthase predicts clinical outcomes of pemetrexed-containing chemotherapy for non-small-cell lung cancer: a systemic review and meta-analysis.
    Liu Y; Yin TJ; Zhou R; Zhou S; Fan L; Zhang RG
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):1125-32. PubMed ID: 24067998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of dUTPase induces synthetic lethality with thymidylate synthase-targeted therapies in non-small cell lung cancer.
    Wilson PM; LaBonte MJ; Lenz HJ; Mack PC; Ladner RD
    Mol Cancer Ther; 2012 Mar; 11(3):616-28. PubMed ID: 22172489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: the association with treatment efficacy of pemetrexed.
    Chen CY; Chang YL; Shih JY; Lin JW; Chen KY; Yang CH; Yu CJ; Yang PC
    Lung Cancer; 2011 Oct; 74(1):132-8. PubMed ID: 21367480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imaging cellular proliferation during chemo-radiotherapy: a pilot study of serial 18F-FLT positron emission tomography/computed tomography imaging for non-small-cell lung cancer.
    Everitt S; Hicks RJ; Ball D; Kron T; Schneider-Kolsky M; Walter T; Binns D; Mac Manus M
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1098-104. PubMed ID: 19386444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using Radiolabeled 3'-Deoxy-3'-
    McHugh CI; Thipparthi MR; Lawhorn-Crews JM; Polin L; Gadgeel S; Akoury J; Mangner TJ; Douglas KA; Li J; Ratnam M; Shields AF
    J Nucl Med; 2018 Oct; 59(10):1544-1550. PubMed ID: 29674424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variability of Proliferation and Diffusion in Different Lung Cancer Models as Measured by 3'-Deoxy-3'-¹⁸F-Fluorothymidine PET and Diffusion-Weighted MR Imaging.
    Schelhaas S; Wachsmuth L; Viel T; Honess DJ; Heinzmann K; Smith DM; Hermann S; Wagner S; Kuhlmann MT; Müller-Tidow C; Kopka K; Schober O; Schäfers M; Schneider R; Aboagye EO; Griffiths J; Faber C; Jacobs AH
    J Nucl Med; 2014 Jun; 55(6):983-8. PubMed ID: 24777288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer.
    Takezawa K; Okamoto I; Okamoto W; Takeda M; Sakai K; Tsukioka S; Kuwata K; Yamaguchi H; Nishio K; Nakagawa K
    Br J Cancer; 2011 May; 104(10):1594-601. PubMed ID: 21487406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thymidylate synthase expression and outcome of patients receiving pemetrexed for advanced nonsquamous non-small-cell lung cancer in a prospective blinded assessment phase II clinical trial.
    Nicolson MC; Fennell DA; Ferry D; O'Byrne K; Shah R; Potter V; Skailes G; Upadhyay S; Taylor P; André V; Nguyen TS; Myrand SP; Visseren-Grul C; Das M; Kerr KM
    J Thorac Oncol; 2013 Jul; 8(7):930-9. PubMed ID: 23722170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer.
    Smit EF; Burgers SA; Biesma B; Smit HJ; Eppinga P; Dingemans AM; Joerger M; Schellens JH; Vincent A; van Zandwijk N; Groen HJ
    J Clin Oncol; 2009 Apr; 27(12):2038-45. PubMed ID: 19307503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapy.
    Sun JM; Han J; Ahn JS; Park K; Ahn MJ
    J Thorac Oncol; 2011 Aug; 6(8):1392-9. PubMed ID: 21716147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenomic assessment of outcomes of pemetrexed-treated patients with adenocarcinoma of the lung.
    Jung M; Lee CH; Park HS; Lee JH; Kang YA; Kim SK; Chang J; Kim DJ; Rha SY; Kim JH; Cho BC
    Yonsei Med J; 2013 Jul; 54(4):854-64. PubMed ID: 23709418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significance of folate receptor alpha and thymidylate synthase protein expression in patients with non-small-cell lung cancer treated with pemetrexed.
    Christoph DC; Asuncion BR; Hassan B; Tran C; Maltzman JD; O'Shannessy DJ; Wynes MW; Gauler TC; Wohlschlaeger J; Hoiczyk M; Schuler M; Eberhardt WE; Hirsch FR
    J Thorac Oncol; 2013 Jan; 8(1):19-30. PubMed ID: 23242435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pemetrexed-containing treatments in the non-small cell lung cancer is -/low thymidylate synthase expression better than +/high thymidylate synthase expression: a meta-analysis.
    Wang L; Wang R; Pan Y; Sun Y; Zhang J; Chen H
    BMC Cancer; 2014 Mar; 14():205. PubMed ID: 24641970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between gene expression profiles and clinical outcome of pemetrexed-based treatment in patients with advanced non-squamous non-small cell lung cancer: exploratory results from a phase II study.
    Fennell DA; Myrand SP; Nguyen TS; Ferry D; Kerr KM; Maxwell P; Moore SD; Visseren-Grul C; Das M; Nicolson MC
    PLoS One; 2014; 9(9):e107455. PubMed ID: 25250715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of thymidine kinase 1 after 5-fluorouracil as a mechanism for 3'-deoxy-3'-[18F]fluorothymidine flare.
    Lee SJ; Kim SY; Chung JH; Oh SJ; Ryu JS; Hong YS; Kim TW; Moon DH
    Biochem Pharmacol; 2010 Nov; 80(10):1528-36. PubMed ID: 20723540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapamycin downregulates thymidylate synthase and potentiates the activity of pemetrexed in non-small cell lung cancer.
    Kawabata S; Chiang CT; Tsurutani J; Shiga H; Arwood ML; Komiya T; Gills JJ; Memmott RM; Dennis PA
    Oncotarget; 2014 Feb; 5(4):1062-70. PubMed ID: 24658085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of thymidylate synthase gene 3'-untranslated region polymorphism with sensitivity of non-small cell lung cancer to pemetrexed treatment: TS gene polymorphism and pemetrexed sensitivity in NSCLC.
    Wang X; Wang Y; Wang Y; Cheng J; Wang Y; Ha M
    J Biomed Sci; 2013 Jan; 20(1):5. PubMed ID: 23350714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.